Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

Launched by HE HUANG · Jan 30, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new approach to help patients with blood cancers who need a special type of treatment called hematopoietic stem cell transplantation (HSCT), but who do not have a matching bone marrow donor. The researchers will be using stem cells from donors whose tissue types do not match perfectly, which is known as HLA mismatched donors. The goal is to create a transplantation plan that can help many patients find a suitable donor and improve their chances of recovery.

To participate in this trial, patients must be adults between 18 and 60 years old and have a blood cancer that requires treatment. They should not have a related donor who matches their tissue type well, nor should they have serious health issues that would prevent them from undergoing the transplant. Those who join the study will receive careful monitoring and support throughout the process. It’s important for potential participants to understand that they will need to sign a consent form to take part in this research. Overall, this trial aims to make it easier for patients to find donors and receive the life-saving treatment they need.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (18-60 years old) with hematological malignancies and indications for hematopoietic stem cell transplantation with no available related human leukocyte antigen (HLA) identical sibling donors;
• • No available donor with HLA high-resolution typing ≥ 9/10 or those who have difficulty finding donors due to urgent medical conditions;
• • No suitable HLA matching haploidentical donor available;
• • There is a suitable donor with mismatched HLA typing;
• • The subjects or their legal representatives shall sign an informed consent form before the start of the clinical study.
• Exclusion Criteria:
• • Patients with severe liver and kidney function (alanine aminotransferase\>2.5 times the upper limit of normal, blood creatinine\>1.5 times the upper limit of normal) and cardiopulmonary dysfunction (New York Heart Association (NYHA) III/IV heart function, ejection fraction\<50%, severe obstructive or restrictive ventilation dysfunction);
• • Merge active infections;
• • Eastern Cooperative Oncology Group (ECOG) score ≥ 2 points;
• • Secondary tumors with merged activity;
• • Severe central nervous system or mental illness leading to the inability to autonomously choose to enter or exit clinical trials;
• • Combine other allo HSCT contraindications.